fbpx Skip to main content

Galleri by GRAIL

Offer Employees Their #1 Ranked Health Benefit1

94% of employees want to know if they have cancer as early as possible.2 Unfortunately, most employee health programs only kick into gear post-diagnosis – and most cancers go undetected until they’ve progressed to an advanced stage when treatment costs are high and outcomes are often fatal.3-6

The Galleri multi-cancer early detection test from GRAIL is a groundbreaking and potentially life-changing advancement in cancer detection for adults with an elevated risk for cancer, such as those aged 50 or older. With the Galleri test, employees could receive the benefits of early detection of more than 50 cancers7 – 45 of which lack recommended screeningthrough a simple blood draw.

Download Brochure Explore Employee Feedback

Biocom California Member Benefits

  • Discounted pricing on Galleri multi-cancer early detection tests for Biocom California members
  • Virtual delivery and wraparound add-on support available
  • Account management including project management, employee workflow review, and implementation plan
  • Comprehensive employee awareness materials & resources
  • Dedicated employer landing page
1 278 respondents were asked to select among benefits packages: 401(k) match, Galleri offering, on-demand telemedicine, genetic risk factor tests, mental health support, condition care coaching, and personal financial advice.
2 Market research data on file 2020. Study demographics included 314 respondents, age 40+, who were employed full-time at larger organizations.
3 Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 18 Regs Research Data, Nov 2018 Sub. Includes persons aged 50 – 79 diagnosed 2006 – 2015. “Early/Localized” includes invasive localized tumors that have not spread beyond organ of origin. “Late/Distant Metastases” includes invasive cancers that have metastasized beyond the organ of origin to other parts of the body.
4 Based on stage II and stage IV breast, colorectal, and lung cancer, and metastatic/non-metastatic pancreatic cancer.
5 Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, et al. Medical Care Costs Associated With Cancer in Integrated Delivery Systems. J Natl Compr Canc Netw. 2018;16(4):402 – 10.
6 DaCosta Byfield S, Nash Smyth E, Mytelka D, et al. Healthcare costs, treatment patterns, and resource utilization among pancreatic cancer patients in a managed care population. J Med Econ. 2013;16(12):1379 – 86.
7 Klein E, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test. Oral presentation at: American Association for Cancer Research; April, 2021; LB013

Power up your savings

Connect With Biocom Purchasing Group Contracts

Related Articles

View More